A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
NCT02232646
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Low feasibility
Conditions
Urologic Malignancies
Renal Cell Carcinoma
Urothelial Carcinoma
Interventions
DRUG:
BBI503
Sponsor
Sumitomo Pharma America, Inc.